Lead Product(s) : ART001
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AccurEdit's ART001 Becomes first Gene Editing Therapy in China with RMAT Status
Details : ART001 is the first gene editing product from China to receive an FDA RMAT designation, highlighting the FDA's recognition of its innovative nature and clinical potential.
Product Name : ART001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 28, 2025
Lead Product(s) : ART001
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ART001
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ART001 is an in vivo gene editing product delivered by LNP for the treatment of Transthyretin amyloidosis (ATTR).
Product Name : ART001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 28, 2025
Lead Product(s) : ART001
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Navepegritide
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in Accomplish China Phase 2 Trial
Details : TransCon CNP (c-type natriuretic peptide prodrug) is a FGFR 3 inhibitor. It is being evaluated for the treatment of children with achondroplasia (ACH) aged 2 to 10 years.
Product Name : TransCon CNP
Product Type : Peptide
Upfront Cash : Inapplicable
November 16, 2023
Lead Product(s) : Navepegritide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : glucocerebrosidase
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CAN103 is a recombinant human glucocerebrosidase enzyme replacement therapy that is being developed to treat Gaucher disease (GD) Types I and III, which are the chronic non-neuronopathic and neuronopathic forms of the disease that constitute the majority...
Product Name : CAN103
Product Type : Enzyme
Upfront Cash : Inapplicable
October 16, 2023
Lead Product(s) : glucocerebrosidase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Navepegritide
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : China Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has approved VISEN's IND application to conduct a phase 2 clinical trial of TransCon TM C-Type Natriuretic Peptide (CNP) for patients with achondroplasia (ACH).
Product Name : TransCon CNP
Product Type : Peptide
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : Navepegritide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable